comparemela.com

Latest Breaking News On - Prnewswire ardelyx inc - Page 4 : comparemela.com

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

/PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative.

United statesCity ofUnited kingdomSan franciscoMike raabClarke futchFosun pharmaKyowa kirin co ltdJapanese ministry healthPrnewswire ardelyx incHealthcare royalty managementArdelyx incHealthcare royalty partnersArdelyx japaneseHealthcare royaltyKyowa kirin

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesMike raabFosun pharmaPrnewswire ardelyx incArdelyx incJefferies healthcare conferenceKyowa kirinKnight therapeuticsPr newswire

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

/PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative.

United statesSan diegoBriane lacyFosun pharmaPrnewswire ardelyx incDrug administrationArdelyx incDisease week conferencePoster presentationsTerm treatmentTenapanor improves abdominal painTreatment satisfactionIrritable bowel syndromeEarly onsetTreating symptomsSerious dehydration

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Three poster presentations continue to highlight the safety and efficacy of IBSRELA based on data from two Phase 3 trials in adults with irritable.

United statesSan diegoBriane lacyFosun pharmaExchange commissionPrnewswire ardelyx incExchange commission onDrug administrationArdelyx incDisease week conferencePoster presentationsTerm treatmentTenapanor improves abdominal painTreatment satisfactionIrritable bowel syndromeEarly onset

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoBriane lacyPrnewswire ardelyx incDrug administrationDisease week conferencePoster presentationsTerm treatmentTenapanor improves abdominal painTreatment satisfactionIrritable bowel syndromeEarly onsetTreating symptomsSerious dehydration

vimarsana © 2020. All Rights Reserved.